Psych MEQs / SAQs · Consultation-liaison psychiatry
Lupus psychosis and attribution in NPSLE (MEQ)
FRANZCP-style MEQ on lupus psychosis, ACR syndromes, attribution, EULAR-aligned management, and family communication.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Syndromes and attribution. ACR psychiatric-relevant CNS syndromes include psychosis, mood disorder, anxiety disorder, cognitive dysfunction, and acute confusional state among the broader 19 NP case definitions. This presentation maps to psychosis (with possible mixed mood features). Attribution to SLE is supported by known SLE, serologic activity (low C3, proteinuria), subacute tempo, and multi-system clues — but is not automatic. Exclude infection, substance use, primary psychotic disorder, steroid toxicity (if doses recently escalated), metabolic encephalopathy, and APS-related processes. Depot-only primary schizophrenia framing is premature.[1][2][3]
(ii) Investigations. Joint rheumatology/CL plan: infection screen (cultures, consider LP if meningism/ACS/fever trajectory, opportunistic pathogens as risk warrants), metabolic panel, urine, anti-dsDNA/complements, aPL panel, consider anti-ribosomal P as supportive for diffuse psychiatric NPSLE, MRI brain (may be normal/non-specific), EEG if fluctuating consciousness/seizure risk. Do not treat a normal MRI as exclusion of diffuse NPSLE.[2][3][4]
(iii) Treatment principles. If inflammatory primary NPSLE psychosis is the working attribution after infection exclusion: high-dose glucocorticoids and immunosuppression per EULAR-aligned practice (classically cyclophosphamide for severe inflammatory CNS disease under rheumatology protocol; alternatives if contraindicated/refractory). If aPL/thrombotic phenotype dominates focal vascular disease, prioritise antithrombotic care. Symptomatic: lowest-effective antipsychotic bridge, e.g. olanzapine 2.5–5 mg oral at night with metabolic/QTc monitoring, while disease-modifying therapy proceeds — psychotropics are not definitive cure.[2][3][5]
(iv) Family and capacity. Explain in plain language that immune activity can affect the brain and produce psychosis; tests exclude infection; treatment may include steroids/immunosuppression plus short-term psychiatric medicine; recovery is often good with early care but needs shared teams. Assess capacity for investigation/treatment; if lacking, use local least-restrictive legal framework for emergency care — state principles, not invented foreign section numbers. Safety plan for suicide/aggression risk.[2][3]
Common errors
- Accepting "just schizophrenia + depot" without organic attribution
- Escalating immunosuppression without infection exclusion
- Treating anti-ribosomal P as pathognomonic rather than supportive
- Ignoring aPL when vascular features are present
- Inventing Mental Health Act section numbers
Examiner notes
Reward structured ACR language, mechanism branching, and collaborative ownership with rheumatology.[1][2][3]
References
- [1]ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes Arthritis Rheum, 1999.PMID 10211873
- [2]Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations Ann Rheum Dis, 2010.PMID 20724309
- [3]Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives Drugs, 2016.PMID 26809245
- [4]Isshi K, Hirohata S Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus Arthritis Rheum, 1996.PMID 8814059
- [5]Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Ann Rheum Dis, 2019.PMID 30926722